Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Teva Pharma (TEVA) Misses Q1 EPS by 15c, Revenue Beats, Offers Guidance
May 10, 2023 7:04 AM EDTTeva Pharma (NYSE: TEVA) reported Q1 EPS of $0.40, $0.15 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $3.7 billion versus the consensus estimate of $3.61 billion.
GUIDANCE:
Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of... More
